Genomic Health, Inc. (NASDAQ:GHDX) Director Bros. Advisors Lp Baker sold 202,134 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $78.49, for a total value of $15,865,497.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

  • On Friday, November 30th, Bros. Advisors Lp Baker sold 256,035 shares of Genomic Health stock. The shares were sold at an average price of $78.95, for a total value of $20,213,963.25.
  • On Monday, November 26th, Bros. Advisors Lp Baker sold 39,675 shares of Genomic Health stock. The shares were sold at an average price of $74.28, for a total value of $2,947,059.00.
  • On Wednesday, November 28th, Bros. Advisors Lp Baker sold 250,392 shares of Genomic Health stock. The shares were sold at an average price of $75.61, for a total value of $18,932,139.12.
  • On Friday, November 16th, Bros. Advisors Lp Baker sold 87,395 shares of Genomic Health stock. The shares were sold at an average price of $76.65, for a total value of $6,698,826.75.
  • On Friday, November 9th, Bros. Advisors Lp Baker sold 169,344 shares of Genomic Health stock. The shares were sold at an average price of $82.51, for a total value of $13,972,573.44.
  • On Tuesday, November 13th, Bros. Advisors Lp Baker sold 204,300 shares of Genomic Health stock. The shares were sold at an average price of $79.33, for a total value of $16,207,119.00.

Shares of NASDAQ:GHDX opened at $73.97 on Thursday. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of 7,397.00 and a beta of 0.40. Genomic Health, Inc. has a 12-month low of $26.54 and a 12-month high of $92.18.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.28. The business had revenue of $101.30 million during the quarter, compared to analysts’ expectations of $94.27 million. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.06) earnings per share. As a group, equities research analysts forecast that Genomic Health, Inc. will post 1.06 EPS for the current fiscal year.

GHDX has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Genomic Health from a “hold” rating to a “buy” rating and set a $67.00 target price for the company in a research note on Wednesday, August 29th. Canaccord Genuity reiterated a “buy” rating and set a $82.00 price objective (up previously from $70.00) on shares of Genomic Health in a research note on Wednesday, November 7th. Raymond James assumed coverage on Genomic Health in a research note on Tuesday, October 23rd. They set a “market perform” rating for the company. Finally, BidaskClub upgraded Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 30th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $48.33.

Large investors have recently made changes to their positions in the business. First Quadrant L P CA raised its stake in Genomic Health by 2,575.5% during the third quarter. First Quadrant L P CA now owns 21,083 shares of the medical research company’s stock valued at $1,480,000 after buying an additional 20,295 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Genomic Health by 30.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 122,246 shares of the medical research company’s stock worth $6,161,000 after purchasing an additional 28,710 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Genomic Health by 4.7% in the 2nd quarter. Northern Trust Corp now owns 282,021 shares of the medical research company’s stock worth $14,214,000 after purchasing an additional 12,597 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Genomic Health by 114.0% in the 2nd quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock worth $72,891,000 after purchasing an additional 770,413 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Genomic Health in the 2nd quarter worth $213,000. Institutional investors and hedge funds own 89.21% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) Director Bros. Advisors Lp Baker Sells 202,134 Shares” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/genomic-health-inc-ghdx-director-bros-advisors-lp-baker-sells-202134-shares/2663706.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Article: Understanding the different types of bonds

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.